Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788)
Sponsor: Shengjing Hospital